

ASX RELEASE

11 April 2016

Release of Shares from Voluntary Escrow

MMJ PhytoTech Limited (ASX:MMJ) (the “Company”) advises in accordance with Listing Rule 3.10A, that 17,510,000 fully paid ordinary shares will be released from voluntary escrow on Wednesday, 27 April 2016.

These 17,510,000 shares to be released from escrow represent the second of three tranches of the Shares issued in relation to the merger with MMJ Bioscience Inc on 27 July 2015 (“Merger Consideration Shares”).

The Company applied for, and was subsequently granted, quotation of the Merger Consideration Shares on 4 August 2015. Holding locks applicable to this second tranche of shares will be lifted prior to the commencement of trade on Wednesday, 27 April 2016.

Following the release of the above shares from escrow, the third and final tranche of the Merger Consideration Shares totalling 17,510,000 fully paid ordinary shares will remain in escrow until 27 October 2016.

The Company also has a further total of 45,416,666 securities (including fully paid ordinary shares, performance rights and options) which remain subject to a 24 month escrow period from the date of the Company’s successful ASX listing on 22 January 2015.

For more information please contact:

Erlyn Dale
Company Secretary
+61 8 9389 3150
info@mmjphytotech.com.au

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

ASX RELEASE

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.

<http://www.mmjphytotech.com.au>